Citius Oncology has announced the US commercial launch of Lymphir, its novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL). The launch follows approval by the US Food and Drug Administration (FDA) in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL). The FDA approval was… Read More
Citius Oncology has partnered with technology company Verix to advance the commercial launch of its novel immunotherapy Lymphir. Lymphir is used for the treatment of adult patients with elapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment was previously approved by the US… Read More
The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More
Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. The high dose formulation of CITI-002, a lidocaine and halobetasol combination formulation, provided a meaningful reduction in symptom severity, as reported by patients, when compared to individual… Read More
